Non-Eye Field Sample Clauses

Non-Eye Field. Notwithstanding Section 4.5(a) (General), and on a Joint Patent-by-Joint Patent basis, for a period of [***] from the applicable Trigger Date for a Joint Patent, (i) Affinia shall have the [***] right to [***] in the Non-Eye Field, [***]. Subject to Section 4.6 (Option Rights of Affinia), upon expiration of such [***] month period, all such restrictions [***] shall expire [***], and [***].
Sample 1
AutoNDA by SimpleDocs
Non-Eye Field. Subject to Affinia’s full funding of the Research Plan Activities and payment of all amounts due to IOB under this Agreement, IOB hereby grants Affinia, an exclusive option to acquire an exclusive (or if Affinia so elects, non-exclusive), worldwide, royalty-bearing license [***] under IOB’s right, title and interest in and to any and all IOB Patents and Joint Patents and associated Collaboration Results, to Research, Develop, manufacture, use, sell, offer for sale, import, export, and commercialize Licensed Products in the Non-Eye Field (the “Option”). Affinia shall have the right to exercise an Option for a period of [***] from the date of [***] such IOB Patent, or [***] a Joint Patent, as applicable, unless otherwise extended by the mutual written agreement of the Parties (the “Option Period”). Upon Affinia’s exercise of an Option during the Option Period for such Option, the Parties shall engage in good faith negotiations on the [***] terms and conditions of a license agreement covering such IOB Patent or Joint Patent (and associated Collaboration Results), as applicable, which license shall contain customary terms and obligations for the type of license being granted, including diligence obligations, and in the case of an exclusive license, will contain the payment as are set forth on Exhibit C, [***]). If (i) Affinia either fails to respond to or elects not to exercise its Option for such disclosed IOB Patent or Joint Patent, as applicable, within such Option Period, or (ii) IOB and Affinia fail to execute a license agreement for such IOB Patent or Joint Patent within [***] after the date of Affinia’s exercise of such Option for such IOB Patent or Joint Patent within [***] after the date of Affinia’s exercise of such Option (or such longer period of time as may be agreed to by the IOB) (such period of time, the “Negotiation Period” and such failure to agree upon the license, a “License Disagreement”), then in the case of each of (i) and (ii), except as provided in Section 4.7(a) (Grant to Affinia), IOB shall be free to license such IOB Patent or Joint Patent, as applicable, in the Non-Eye Field to a Third Party without any further obligation to Affinia, [***].
Sample 1
Non-Eye Field. Notwithstanding [***] ownership rights in and to the Collaboration Results, Affinia shall have the [***] right [***] to make, use, [***] exploit, [***] Collaboration Results[***] in the Non-Eye Field, [***]. Notwithstanding [***] IOB shall have the right to[***] Collaboration Results[***] in the Non-Eye Field[***].
Sample 1

Related to Non-Eye Field

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

  • Licensed Territory Worldwide NIH Patent License Agreement—Exclusive APPENDIX C – ROYALTIES Royalties:

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Research License Following Selection of each CGI Antigen (or exercise of a Buy-In Right for each CGI Antigen) and subject to the terms and conditions of this Agreement, ABX agrees to grant, and hereby grants, to CGI a nonexclusive sublicense under the Licensed Technology to develop, make, have made, use, import or export or otherwise transfer physical possession of (but not to sell, lease, offer to sell or lease, or otherwise transfer title to) Covered Products related to such CGI Antigen and cells that express or secrete Antibodies to such CGI Antigen, in each case solely for purposes relating to or in connection with research or development (i) of Covered Products for use in the field of Gene Therapy or (ii) involving Genetic Material when used with viral or nonviral gene transfer systems. CGI shall have the right to sublicense the rights granted under this Section 2.5 upon the approval of ABX, which approval shall not be unreasonably withheld. In the event that ABX refuses to approve such a sublicense, ABX shall, to the extent that ABX has the right to do so, grant at CGI's request a nonexclusive sublicense of such rights directly to a non-Affiliate third party designated by CGI on terms and conditions substantially identical to the applicable terms and conditions of this Agreement. The sublicense granted by ABX under this Section 2.5 with respect to a CGI Antigen (and the further sublicenses, if any, granted by CGI under this Section 2.5 with respect to such CGI Antigen) shall terminate at such time as (A) CGI sends ABX an Abandonment Notice pursuant to Section 2.4.1 above regarding such CGI Antigen or (B) CGI enters into a CGI Product Sublicense related to such CGI Antigen; provided, however, that termination of a sublicense under this Section 2.5 with respect to a CGI Antigen pursuant to (B) above shall not affect the duration or survival of a grant of similar rights or sublicense under the CGI Product Sublicense with respect to such CGI Antigen, which rights or sublicense shall terminate or expire only in accordance with the terms of such CGI Product Sublicense. In the event that ABX enters into a Product Sublicense with respect to a CGI Antigen and CGI has not within six (6) months thereafter entered into a CGI Product Sublicense with respect to such CGI Antigen, the sublicense granted under this Section 2.5 with respect to such CGI Antigen shall terminate. It is understood and agreed that (x) as to ABX-Controlled Rights, the grant of rights under this Section 2.5 shall be subject to and limited in all respects by the terms of the applicable ABX In-License(s) pursuant to which such ABX-Controlled Rights were granted to ABX and (y) the rights and sublicenses granted to CGI under this Section 2.5 or any other provision of this Agreement shall be subject in all respects to the GenPharm Cross License.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • License; Use Upon delivery to an Authorized Person or a person reasonably believed by Custodian to be an Authorized Person of the Fund of software enabling the Fund to obtain access to the System (the “Software”), Custodian grants to the Fund a personal, nontransferable and nonexclusive license to use the Software solely for the purpose of transmitting Written Instructions, receiving reports, making inquiries or otherwise communicating with Custodian in connection with the Account(s). The Fund shall use the Software solely for its own internal and proper business purposes and not in the operation of a service bureau. Except as set forth herein, no license or right of any kind is granted to the Fund with respect to the Software. The Fund acknowledges that Custodian and its suppliers retain and have title and exclusive proprietary rights to the Software, including any trade secrets or other ideas, concepts, know-how, methodologies, or information incorporated therein and the exclusive rights to any copyrights, trademarks and patents (including registrations and applications for registration of either), or other statutory or legal protections available in respect thereof. The Fund further acknowledges that all or a part of the Software may be copyrighted or trademarked (or a registration or claim made therefor) by Custodian or its suppliers. The Fund shall not take any action with respect tot the Software inconsistent with the foregoing acknowledgement, nor shall the Fund attempt to decompile, reverse engineer or modify the Software. The Fund may not xxx, sell, lease or provide, directly or indirectly, any of the Software of any portion thereof to any other person or entity without Custodian’s prior written consent. The Fund may not remove any statutory copyright notice or other notice included in the Software or on any media containing the Software. The Fund shall reproduce any such notice on any reproduction of the Software and shall add any statutory copyright notice or other notice to the Software or media upon Custodian’s request.

  • Research Licenses The Parties shall, and do hereby grant to each other all required licenses (on a non-exclusive, non-sublicenseable, royalty-free, for research and development purposes only basis) in respect of an individual Party’s Intellectual Property necessary for the other Party to conduct the activities contemplated hereunder this Agreement.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!